

Oncology Today with Dr Neil Love: Advances in Genetic Profiling and Targeted Therapies for Colorectal Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following patient populations derived the greatest progression-free survival benefit from treatment with cetuximab and irinotecan in the Phase II CRICKET trial?
  - a. Patients with RAS-mutated circulating tumor DNA (ctDNA)
  - b. Patients with RAS wild-type ctDNA
2. Which of the following conditions is a common Grade  $\geq 3$  adverse event associated with the multikinase inhibitor regorafenib?
  - a. Headache
  - b. Dysphonia
  - c. Fatigue
  - d. Proteinuria
3. The ReDOS trial comparing dose escalation to a standard dose of regorafenib reported which of the following outcomes for its primary endpoint?
  - a. Dose escalation resulted in a significantly greater proportion of patients initiating cycle 3
  - b. No significant difference was reported in the number of patients initiating cycle 3
4. Which of the following drugs or drug combinations targeting KRAS G12C (with or without EGFR) was associated with the highest response rate according to reports at ESMO 2021?
  - a. Sotorasib
  - b. Adagrasib
  - c. Sotorasib/panitumumab
  - d. Adagrasib/cetuximab